Loading…
← CockpitCompetitor Analysis › PRTA Prothena Corp. PlcOpen in the cockpit ↗

Prothena Corp. PlcPRTACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum neutral 43
Mkt cap
$429M
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$3.95M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$8.35
1D+1.1%
1W-4.3%
1M-1.8%
3M-7.5%
6M-10.7%
YTD-12.6%
1Y-18.5%
ATR %5.4%
Beta1.08
52w lowhigh29.2% off high

What Prothena does

Employees: 67

Prothena at a glance

Size Prothena (PRTA) is a United States Health Care company (Biotechnology) with a market value of $429M, the 2789th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.35 on 18 Nov 2026.

Performance Over six months the shares fell 10.7%, against -19.5% for the median peer and -2.2% for the United States market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 347.4% over the last twelve months (peer median -1.8%); the operating margin is -73.0% (peer median -7.3%).

Valuation It trades at 3.1× enterprise value to sales against a peer median of 10.3× (5th cheapest of 16).

Short interest Short interest is 15.4% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026PRTA 89Peer median 80
Six months, rebased to 100: Prothena against the median of its 20 peers (local-currency closes).

Prothena financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$52.7M$9.68M$135M$91.4M$53.9M
Revenue growth—-93%+48%+70%—
Gross profit$49.0M$5.98M$132M$83.0M$47.2M
EBITDA-$34.8M-$181M-$151M-$183M-$125M
Net income-$24.0M-$244M-$122M-$147M-$117M
Free cash flow-$30.8M-$164M-$150M-$137M-$109M
Capital expenditure$716,408$138,000$298,000$2.81M$464,000
Total debt$6.26M$8.37M$10.8M$11.8M$6.47M

Quarterly statements and history in the cockpit →

Prothena competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-20%0%2509671265471789688317603739000710IRLA476830CADL456160688163EPRXARVN658968823869983378115180PRTA6-month return →1-month return →
Up and to the right = strong over both horizons. Prothena is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×500×2509671265474768304561606998115180PRTARevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Prothena is the large dot.

Prothena competitors and peer comparison

How Prothena compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Prothena against its 20 peers (data as of 18 Nov 2026)
MeasurePRTAPeer medianRank in peer set
1-month return-1.8%-13.3%3rd highest of 21
6-month return-10.7%-19.5%9th highest of 21
Distance from 52-week high-29.2%-42.7%3rd highest of 21
Revenue growth (TTM)+347.4%-1.8%2nd highest of 17
Operating margin-73.0%-7.3%5th lowest of 17
EV / Sales3.1×10.3×5th cheapest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%14.6×n/an/a
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%2.9×4.0%-62.3%
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%908.6×n/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%10.6×n/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Arvinas ARVNUnited States$443M-26%-12%-10%n/an/an/a
EirGenix 6589.TWTaiwan$444M+15%+58%-51%9.9×n/an/a
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%10.3×n/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%1.0×-15.3%+197.3%
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Qurient 115180.KSSouth Korea$452M-56%-14%-512%84.4×n/an/a
Komipharm International 041960.KSSouth Korea$454M-2%-6%-1%11.8×n/an/a

Questions

Which companies are Prothena's closest peers?
The cockpit's peer set: Qyuns Therapeutics (2509.HK), Ever Supreme Bio Technology (6712.TWO), Medigen Vaccine Biologics (6547.TWO), Scinopharm Taiwan (1789.TW), Shanghai ZJ Bio-Tech (688317.SS), Qingdao Vland Biotech (603739.SS), Berry Genomics (000710.SZ), IRulya Therapeutics (IRLA).
Is Prothena expensive compared with its peers?
On ev / sales it trades at 3.1× against a peer median of 10.3×, 5th cheapest of 16 in its peer set.
How has Prothena stock performed?
Over six months to 18 Nov 2026 the shares returned -10.7% against -19.5% for the median peer; over one year -18.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.